Post hoc exploratory analysis of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma from the randomized, placebo-controlled phase III study ARIEL3: Effect of a deleterious germline or no germline BRCA mutation on efficacy Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Coleman, R. L.; Oza, A. M.; Lorusso, D.; Aghajanian, C. A.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; Leary, A.; Holloway, R. W.; Amenedo Gancedo, M.; Fong, P. C. C.; Goh, J. C.; O'Malley, D. M.; Banerjee, S.; Goble, S.; Cameron, T.; Ledermann, J. A.

authors

Publication Date

  • June 1, 2019

webpage

published in

category

start page

  • 237

end page

  • 237

volume

  • 154